Carnitine depletion as a probable cause of hyperlipidemia in uremic patients on maintenance hemodialysis.

Maebashi, Masaru; Imamura, Akira; Yoshinaga, Kaoru; Sato, Takao; Funyu, Tomihisa; Ishidoya, Y; Hirayama, Naoki

doi:10.1620/tjem.139.33

Cited by 10 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results have been con firmed by Vacha et al [12] and Maebashi et al [28], A significant decrease of elevated serum triglycerides was also described by Guarnieri et al [24] and Bertoli et al [14] in HD patients after carnitine administration, whereas total cholesterol remained unchanged. In the present study, total cholesterol.…”

Section: Discussionsupporting

confidence: 69%

Serum Free Carnitine, Carnitine Esters and Lipids in Patients on Peritoneal Dialysis and Hemodialysis

et al. 1986

View full text Add to dashboard Cite

Serum free and esterified carnitine levels as well as lipids were investigated in patients undergoing regular hemodialysis (HD) treatment before and during 12 weeks of treatment with L-carnitine (1 g i.v.) at the end of each HD. The results were compared with those obtained in patients on continuous ambulatory peritoneal dialysis (CAPD; n = 15) or intermittent peritoneal dialysis (IPD; n = 3) and healthy controls (CO; n = 20). In HD patients (n = 23) total carnitine (TC) was 49.9 ± 3.9 (CO: 46.0 ± 2.5; NS), free carnitine (FC) was 31.6 ± 2.8 (CO: 37.4 ± 1.3; p < 0.05), short-chain acylcarnitine (SCC) was 17.0 ± 1.8 (CO: 7.2 ± 0.9; p < 0.0001) and long-chain acylcarnitine (LCC) was 1.2 ± 0.2 μmol/l (CO: 0.6 ± 0.1; p < 0.05). FC was in the normal range in CAPD (35.6 ± 3.2) and IPD (44.5 ± 8.0 μmol/l) patients, whereas SCC (30.1 ± 3.5) and LCC (2.9 ± 0.2) levels were maximal elevated in IPD patients (11.8 ± 0.8 and 1.5 ± 0.2 on CAPD). Therefore, TC was higher in IPD than in CAPD patients (77.5 ± 5.0 vs. 49.0 ± 3.5 μmol/l). 12 weeks after L-carnitine supplementation in HD patients, TC was 313.9 ± 22.6, FC was 207.7 ± 12.4, SCC was 99.6 ± 12.1 and LCC was 7.1 ± 0.6 μmol/l. TC and FC were significantly lower in females compared with males. Total cholesterol and ketone bodies were normal, HDL cholesterol was significantly decreased before and after L-carnitine supplementation. On the other hand, a paradoxical rise in serum triglycerides was observed. Our data indicate abnormalities of free and esterified carnitine in HD, CAPD and IPD patients. The markedly elevated serum levels for TC, FC, SCC and LCC following L-carnitine therapy suggest limited carnitine utilization in chronic uremic patients.

show abstract

Section: Discussionsupporting

confidence: 69%

Serum Free Carnitine, Carnitine Esters and Lipids in Patients on Peritoneal Dialysis and Hemodialysis

et al. 1986

View full text Add to dashboard Cite

show abstract

“…Furthermore, pindolol proved essentially inactive on carnitine metabolism, with the only exception being a significant increase in carnitine level in the adipose tissue, although carnitine was effective in lowering plasma TG and VLDL in hyperlipideconcentrations of lipid lipoprotein and earn itine mic patients (Maebashi et al 1978(Maebashi et al , 1983). The present study showed that the body weight of the pindolol-treated rats was significantly lower than that of the control ones.…”

Section: Lipid and Lipoprotein Concentrations In Plasmamentioning

confidence: 99%